-
Article
Open AccessNeoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The imp...
-
Article
Can Clinical Response Predict Pathologic Response Following Neoadjuvant Chemoradiation for Esophageal Cancer?
Approximately 20–40% of patients with locally advanced esophageal cancer will achieve a pathologic complete response (ypCR) following neoadjuvant chemoradiotherapy (nCRT). Predicting ypCR based on a clinical c...
-
Article
Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy
Most patients undergoing esophagectomy will experience intermittent reflux of gastric and biliary content into the remnant esophagus postoperatively. The incidence of new or recurrent intestinal metaplasia fol...
-
Article
Open AccessIdentification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues
Immune profiling is becoming a vital tool for identifying predictive and prognostic markers for translational studies. The study of the tumor microenvironment (TME) in paraffin tumor tissues such as malignant ...
-
Chapter
Salvage Esophagectomy for Persistent or Recurrent Disease After Chemoradiation
Neoadjuvant chemoradiation is currently used by many cancer centers as the initial treatment for locoregionally-advanced esophageal cancer, with many patients achieving clinical complete response. The choice t...
-
Article
Open AccessGeriatric trauma hip fractures: is there a difference in outcomes based on fracture patterns?
Annually in the US, there are over 300,000 hospital admissions due to hip fractures in geriatric patients. Consequently, there have been several large observational studies, which continue to provide new insig...
